 |
 |
 |
 |
 |
 |
 |
|
|
|
|||||||||
|
|||||||||||
Associate Professor of Clinical Pharmacy, School of Pharmacy, Northeastern University, Boston, MA; Consultant Pharmacist, Boston Veterans Affairs Medical Center, Boston
Reprints: Dr. Cersosimo, School of Pharmacy, Northeastern University, Boston, MA 02115-5000, fax 617/373-7655, r.cersosimo{at}neu.edu
OBJECTIVE: To review the incidence, mechanism, signs, symptoms, and management of oxaliplatin-induced neurotoxicity.
DATA SOURCES: English-language publications from the MEDLINE database (1995–August 2004), published articles, and meeting abstracts were reviewed.
STUDY SELECTION AND DATA EXTRACTION: Relevant data were extracted from published reports and abstracts on studies and case reports of humans with cancer who received oxaliplatin chemotherapy and in vitro studies of oxaliplatin neurotoxicity.
DATA SYNTHESIS: Neurotoxicity is a common adverse effect of
oxaliplatin that usually presents as peripheral neuropathy. There are 2 forms
of oxaliplatin-induced neurotoxicity: acute and chronic. The acute form occurs
in >90% of patients and may begin during the infusion or within hours of
completion, is usually self-limited, and may be exacerbated by exposure to
cold. Chronic neuropathy is cumulative and is most commonly seen in patients
who have received total doses 
540 mg/m2. Although it is
a sensory neuropathy, the intensity can increase to the point that it impairs
physical functions, such as holding objects and writing. Preventive measures
include administration of calcium and magnesium solutions, gabapentin,
carbamazepine, amifostine, and glutathione. Treatment measures include calcium
and magnesium solutions, gabapentin, and 
-lipoic acid.
CONCLUSIONS: Peripheral neuropathy is seen in the majority of patients who receive oxaliplatin. The acute form is usually transient and self-limited; however, the chronic form can be dose-limiting. Calcium and magnesium solutions are an effective and convenient means of treating and reducing the severity of neuropathic symptoms. Additional studies, including controlled trials, are needed to determine the best way to prevent and treat this complication.
Key Words: neuropathy, neurotoxicity, oxaliplatin
Published Online, December 8, 2004. www.theannals.com, DOI 10.1345/aph.1E319
This article has been cited by other articles:
|
|
 |
|
  K. M. Field, S. Kosmider, M. Jefford, R. Jennens, M. Green, and P. Gibbs Chemotherapy Treatments for Metastatic Colorectal Cancer: Is Evidence-Based Medicine in Practice? J. Oncol. Pract, November 1, 2008; 4(6): 271 - 276. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J van Gijn Sensory polyneuropathy Practical Neurology, December 1, 2006; 6(6): 388 - 389. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Berretta, A. Lleshi, F. Di Benedetto, A. Bearz, M. Spina, and U. Tirelli Oxaliplatin and capecitabine (Xelox) in association with highly active antiretroviral therapy in advanced hepatocarcinoma HIV/HCV-infected patients. Ann. Onc., July 1, 2006; 17(7): 1176 - 1177. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Lecomte, B. Landi, P. Beaune, P. Laurent-Puig, and M.-A. Loriot Glutathione S-Transferase P1 Polymorphism (Ile105Val) Predicts Cumulative Neuropathy in Patients Receiving Oxaliplatin-Based Chemotherapy. Clin. Cancer Res., May 15, 2006; 12(10): 3050 - 3056. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Berretta, C. Simonelli, A. Lleshi, T. Lacchin, A. Bearz, G. di Gennaro, E. Vaccher, and U. Tirelli Oxaliplatin-based chemotherapy in association with highly active antiretroviral therapy in metastatic colorectal cancer HIV-infected patients Ann. Onc., April 1, 2006; 17(4): 721 - 722. [Full Text] [PDF]
|
|
 |
 |
 |
 |
 |
 |
 |
